Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition
Reich, Siegfried H, Sprengeler, Paul A, Chiang, Gary G, Appleman, James R, Chen, Joan, Clarine, Jeff, Eam, Boreth, Ernst, Justin T, Han, Qing, Goel, Vikas K, Han, Edward Z. R, Huang, Vera, Hung, Ivy N. J, Jemison, Adrianna, Jessen, Katti A, Molter, Jolene, Murphy, Douglas, Neal, Melissa, Parker, Gregory S, Shaghafi, Michael, Sperry, Samuel, Staunton, Jocelyn, Stumpf, Craig R, Thompson, Peggy A, Tran, Chinh, Webber, Stephen E, Wegerski, Christopher J, Zheng, Hong, Webster, Kevin R
Published in Journal of medicinal chemistry (26.04.2018)
Published in Journal of medicinal chemistry (26.04.2018)
Get full text
Journal Article
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment
Shibuya, Kendall C, Goel, Vikas K, Xiong, Wei, Sham, Jonathan G, Pollack, Seth M, Leahy, Allison M, Whiting, Samuel H, Yeh, Matthew M, Yee, Cassian, Riddell, Stanley R, Pillarisetty, Venu G
Published in PloS one (02.05.2014)
Published in PloS one (02.05.2014)
Get full text
Journal Article
Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors
Gerson-Gurwitz, Adina, Young, Nathan P, Goel, Vikas K, Eam, Boreth, Stumpf, Craig R, Chen, Joan, Fish, Sarah, Barrera, Maria, Sung, Eric, Staunton, Jocelyn, Chiang, Gary G, Webster, Kevin R, Thompson, Peggy A
Published in Frontiers in oncology (24.11.2021)
Published in Frontiers in oncology (24.11.2021)
Get full text
Journal Article
Band 3 Is a Host Receptor Binding Merozoite Surface Protein 1 during the Plasmodium falciparum Invasion of Erythrocytes
Goel, Vikas K., Li, Xuerong, Chen, Huiqing, Liu, Shih-Chun, Chishti, Athar H., Oh, Steven S.
Published in Proceedings of the National Academy of Sciences - PNAS (29.04.2003)
Published in Proceedings of the National Academy of Sciences - PNAS (29.04.2003)
Get full text
Journal Article
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Pecci, Federica, Nakazawa, Seshiru, Ricciuti, Biagio, Harada, Guilherme, Lee, Jessica K, Alessi, Joao V, Barrichello, Adriana, Vaz, Victor R, Lamberti, Giuseppe, Di Federico, Alessandro, Gandhi, Malini M, Gazgalis, Dimitris, Feng, William W, Jiang, Jie, Baldacci, Simon, Locquet, Marie-Anaïs, Gottlieb, Felix H, Chen, Monica F, Lee, Elinton, Haradon, Danielle, Smokovich, Anna, Voligny, Emma, Nguyen, Tom, Goel, Vikas K, Zimmerman, Zachary, Atwal, Sumandeep, Wang, Xinan, Bahcall, Magda, Heist, Rebecca S, Iqbal, Sumaiya, Gandhi, Nishant, Elliott, Andrew, Vanderwalde, Ari M, Ma, Patrick C, Halmos, Balazs, Liu, Stephen V, Che, Jianwei, Schrock, Alexa B, Drilon, Alexander, Jänne, Pasi A, Awad, Mark M
Published in Cancer discovery (02.08.2024)
Published in Cancer discovery (02.08.2024)
Get full text
Journal Article
Erythrocyte calpain is dispensable for malaria parasite invasion and growth
Hanspal, Manjit, Goel, Vikas K, Oh, Steven S, Chishti, Athar H
Published in Molecular and biochemical parasitology (01.07.2002)
Published in Molecular and biochemical parasitology (01.07.2002)
Get full text
Journal Article
Abstract 1444: TPX-0022, a potent MET/SRC/CSF1R inhibitor that modulates the tumor immune microenvironment in preclinical models
Goel, Vikas K., Deng, Wei, zhai, Dayong, Lee, Nathan V., Parra, Ana, Murray, Brion W.
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022)
Pecci, Federica, Ricciuti, Biagio, Alessi, Joao Victor Machado, Barrichello, Adriana Paula de Castro, Vaz, Victor R., Lamberti, Giuseppe, Lee, Jessica Kim, Schrock, Alexa Betzig, Goel, Vikas K, Zimmerman, Zach, Bahcall, Magda, Janne, Pasi A., Awad, Mark M.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Abstract 4142: Physical and functional interactions between MNK and mTOR signaling regulate the activation and differentiation of T cells
Stumpf, Craig R., Goel, Vikas K., Sharma, Rajesh K., Chiang, Gary G., Thompson, Peggy A., Webster, Kevin R.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
Abstract 1955: Inhibition of eIF4A by eFT226 blocks KRAS mutant tumor growth
Stumpf, Craig R., Goel, Vikas K., Chen, Joan, Staunton, Jocelyn, Santori, Emily M., Barrera, Maria, Howard, Haleigh, Webster, Kevin R., Chiang, Gary G., Thompson, Peggy A.
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Abstract 3855: Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response
Stumpf, Craig R., Chen, Joan, Goel, Vikas K., Parker, Gregory S., Chiang, Gary G., Thompson, Peggy A., Webster, Kevin R.
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Abstract 5546: eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, regulates T-cell differentiation promoting an antitumor immune response
Sharma, Rajesh K., Goel, Vikas K., Staunton, Jocelyn, Barrera, Maria, Parra, Ana, Sung, Eric, Chiang, Gary G., Webster, Kevin R.
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Abstract LB-068: Tomivosertib (eFT508), a potent and highly selective inhibitor of MNK1 and MNK2, enhances CAR T cell activity through modulating T cell differentiation
Goel, Vikas K., Sharma, Rajesh K., Staunton, Jocelyn, Stumpf, Craig R., Young, Nathan P., Thompson, Peggy A., Chiang, Gary G., Webster, Kevin R.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
Abstract 1302: Targeting hormone receptor-dependent cancers with potent, selective and orally-available small molecule inhibitors of eIF4E
Chiang, Gary G., Parker, Gregory S., Hung, Ivy N., Goel, Vikas K., Staunton, Jocelyn, Barrera, Maria, Sung, Eric, Parra, Ana, Stumpf, Craig R., Chen, Joan, Thompson, Peggy A., Nevarez, Andreas, Wegerski, Christopher J., Parker, Cody, Clarine, Jeff, Sperry, Samuel, Xiang, Alan, Nilewski, Christian, Packard, Garrick K., Urkalan, Kaveri, Mukaiyama, Takasuke, Michels, Theo, Ernst, Justin T., Sprengeler, Paul A., Reich, Siegfried H., Webster, Kevin R.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers
Thompson, Peggy A, Young, Nathan P, Stumpf, Craig R, Eam, Boreth, Goel, Vikas K, Chen, Joan, Fish, Sarah, Parker, Gregory S, Gerson-Gurwitz, Adina, Barrera, Maria, Sung, Eric, Staunton, Jocelyn, Chiang, Gary G, Wegerski, Christopher J, Sperry, Samuel, Webster, Kevin R, Reich, Siegfried H
Published in Molecular cancer therapeutics (01.12.2019)
Published in Molecular cancer therapeutics (01.12.2019)
Get full text
Journal Article
Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity
Webster, Kevin R., Goel, Vikas K., Staunton, Jocelyn, Stumpf, Craig R., Sharma, Rajesh, Hung, Ivy N., Parker, Gregory S., Molter, Jolene, Chiang, Gary G., Wegerski, Christopher J., Sperry, Samuel, Huang, Vera, Chen, Joan, Thompson, Peggy A., Tran, Chinh, Ernst, Justin T., Sprengeler, Paul A., Reich, Siegfried H.
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Get full text
Journal Article
Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade
Webster, Kevin R., Goel, Vikas K., Staunton, Jocelyn, Hung, Ivy NJ, Parker, Gregory S., Stumpf, Craig R., Molter, Jolene, Chiang, Gary G., Wegerski, Christopher J., Sperry, Samuel, Chen, Joan, Huang, Vera, Thompson, Peggy A., Tran, Chinh, Ernst, Justin T., Webber, Stephen E., Sprengeler, Paul A., Reich, Siegfried H.
Published in Cancer research (Chicago, Ill.) (15.03.2017)
Published in Cancer research (Chicago, Ill.) (15.03.2017)
Get full text
Journal Article
eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)
Webster, Kevin R., Goel, Vikas K, Hung, Ivy NJ, Parker, Gregory S, Staunton, Jocelyn, Neal, Melissa, Molter, Jolene, Chiang, Gary G, Jessen, Katti A., Wegerski, Christopher J, Sperry, Samuel, Huang, Vera, Chen, Joan, Thompson, Peggy A, Appleman, James R, Webber, Stephen E, Sprengeler, Paul A, Reich, Siegfried H
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article